Associate Professor Stephen Shumack

OAM
Clinical Associate Professor
Dermatology, Northern Clinical School

Telephone 02 9221 1477
Fax 02 9231 5968

Map

Selected publications

Download citations: PDF RTF Endnote

Journals

  • See, J., Shumack, S., Murrell, D., Rubel, D., Fernandez Penas, P., Salmon, R., Hewitt, D., Foley, P., Spelman, L. (2016). Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia. Australasian Journal of Dermatology, 57(3), 167-174. [More Information]
  • Baker, C., Mack, A., Cooper, A., Fischer, G., Shumack, S., Sidhu, S., Soyer, H., Wu, J., Chan, J., Nash, P., et al (2016). Treatment goals for moderate to severe psoriasis: An Australian consensus. Medicine Today, 17(1-2), 46-54.
  • Werner, R., Stockfleth, E., Connolly, S., Correia, O., Erdmann, R., Foley, P., Gupta, A., Jacobs, A., Kerl, H., Lim, H., Shumack, S., et al (2015). Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. European Academy of Dermatology and Venereology. Journal, 29(11), 2069-2079. [More Information]
  • Dodd, A., Chia, A., Shumack, S. (2014). Actinic Keratosis: Rationale and Management. Dermatology and Therapy, 4(1), 11-31. [More Information]
  • Anderson, L., Jarratt, M., Schmieder, G., Shumack, S., Katsamas, J., Welburn, P. (2014). Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis. The Journal of Clinical and Aesthetic Dermatology, 7(12), 19-29.
  • Lebwohl, M., Shumack, S., Stein Gold, L., Melgaard, A., Larsson, T., Tyring, S. (2013). Long-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses. JAMA Dermatology, 149(6), 666-670. [More Information]
  • Baker, C., Mack, A., Cooper, A., Fischer, G., Shumack, S., Sidhu, S., Soyer, P., Wu, J., Chan, J., Nash, P., et al (2013). Treatment goals for moderate to severe psoriasis: an Australian consensus. Australasian Journal of Dermatology, 54(2), 148-154. [More Information]

2016

  • See, J., Shumack, S., Murrell, D., Rubel, D., Fernandez Penas, P., Salmon, R., Hewitt, D., Foley, P., Spelman, L. (2016). Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in Australia. Australasian Journal of Dermatology, 57(3), 167-174. [More Information]
  • Baker, C., Mack, A., Cooper, A., Fischer, G., Shumack, S., Sidhu, S., Soyer, H., Wu, J., Chan, J., Nash, P., et al (2016). Treatment goals for moderate to severe psoriasis: An Australian consensus. Medicine Today, 17(1-2), 46-54.

2015

  • Werner, R., Stockfleth, E., Connolly, S., Correia, O., Erdmann, R., Foley, P., Gupta, A., Jacobs, A., Kerl, H., Lim, H., Shumack, S., et al (2015). Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic Keratosis - International League of Dermatological Societies in cooperation with the European Dermatology Forum - Short version. European Academy of Dermatology and Venereology. Journal, 29(11), 2069-2079. [More Information]

2014

  • Dodd, A., Chia, A., Shumack, S. (2014). Actinic Keratosis: Rationale and Management. Dermatology and Therapy, 4(1), 11-31. [More Information]
  • Anderson, L., Jarratt, M., Schmieder, G., Shumack, S., Katsamas, J., Welburn, P. (2014). Tolerability and Pharmacokinetics of Ingenol Mebutate 0.05% Gel Applied to Treatment Areas up to 100cm(2) on the Forearm(s) of Patients with Actinic Keratosis. The Journal of Clinical and Aesthetic Dermatology, 7(12), 19-29.

2013

  • Lebwohl, M., Shumack, S., Stein Gold, L., Melgaard, A., Larsson, T., Tyring, S. (2013). Long-term Follow-up Study of Ingenol Mebutate Gel for the Treatment of Actinic Keratoses. JAMA Dermatology, 149(6), 666-670. [More Information]
  • Baker, C., Mack, A., Cooper, A., Fischer, G., Shumack, S., Sidhu, S., Soyer, P., Wu, J., Chan, J., Nash, P., et al (2013). Treatment goals for moderate to severe psoriasis: an Australian consensus. Australasian Journal of Dermatology, 54(2), 148-154. [More Information]

To update your profile click here. For support on your academic profile contact .